Marker Therapeutics (MRKR) Amortizatization of Intangibles (2014 - 2023)
Marker Therapeutics (MRKR) reported Amortizatization of Intangibles of $153518.0 for Q1 2023, down 40.47% year-over-year from $257889.0 in Q1 2022, and up 1.07% quarter-over-quarter from $151897.0 in Q4 2022.
Marker Therapeutics (MRKR) Amortizatization of Intangibles (2014 - 2023) Analysis & Trends
Marker Therapeutics (MRKR) has 6 years of Amortizatization of Intangibles data on file, last reported at $153518.0 in Q1 2023.
- Amortizatization of Intangibles for Q1 2023 came in at $153518.0, down 40.47% year-over-year; the trailing twelve-month figure through Mar 2023 was $786972.0 (down 22.84% YoY), and the FY2022 annual result was $891343.0, down 12.07% from the prior year.
- Amortizatization of Intangibles climbed to $153518.0 in Q1 2023 per MRKR's latest filing, from $151897.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $259170.0 in Q2 2022 and troughed at $44211.0 in Q1 2019.
- A 5-year average of $166471.4 and a median of $222387.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2020 and 2022: Amortizatization of Intangibles soared 442.56% in 2020, then slumped 40.59% in 2022.
- A 5-year view of Amortizatization of Intangibles shows it stood at $46540.0 in 2019, then soared by 442.56% to $252509.0 in 2020, then climbed by 1.26% to $255697.0 in 2021, then sank by 40.59% to $151897.0 in 2022, then grew by 1.07% to $153518.0 in 2023.
- Business Quant data shows MRKR's Amortizatization of Intangibles at $153518.0 in Q1 2023, $151897.0 in Q4 2022, and $222387.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Marker Therapeutics | 27.62 Mn | 27.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 153,518.00 |
| Mar 31, 2023 | 153,518.00 |
| Dec 31, 2022 | 151,897.00 |
| Dec 31, 2022 | 151,897.00 |
| Sep 30, 2022 | 222,387.00 |
| Sep 30, 2022 | 222,387.00 |
| Jun 30, 2022 | 259,170.00 |
| Jun 30, 2022 | 259,170.00 |
| Mar 31, 2022 | 257,889.00 |
| Mar 31, 2022 | 257,889.00 |
| Dec 31, 2021 | 255,697.00 |
| Dec 31, 2021 | 255,697.00 |
| Sep 30, 2021 | 253,726.00 |
| Sep 30, 2021 | 253,726.00 |
| Jun 30, 2021 | 252,606.00 |
| Jun 30, 2021 | 252,606.00 |
| Mar 31, 2021 | 251,626.00 |
| Mar 31, 2021 | 251,626.00 |
| Dec 31, 2020 | 252,509.00 |
| Dec 31, 2020 | 252,509.00 |